Department of Biology and Biochemistry, University of Bath , Bath, UK.
Department of Medicine, Baylor College , Houston, TX, USA.
Expert Rev Clin Pharmacol. 2020 Jun;13(6):623-629. doi: 10.1080/17512433.2020.1767591. Epub 2020 May 22.
Hepatocellular carcinoma (HCC) is one of the most frequent tumors affecting the gastrointestinal tract and a universal cause of morbidity and mortality. Cabozantinib is a strong multi-inhibitor of receptor tyrosine kinases approved for renal cell carcinoma that could be useful also for the treatment of HCC.
This review describes the chemical structure, the pharmacologic properties and current knowledge of the efficacy of cabozantinib in the treatment of HCC based on data available from first phase and later phase clinical trials. The ongoing studies testing cabozantinib, either alone or in combination with other drugs, are also described.
Despite the recent achievements in the use of cabozantinib for patients diagnosed with hepatocellular carcinoma, data are still needed to allow clinicians to make better decisions on how to treat specific patient subgroups.
肝细胞癌（HCC）是影响胃肠道最常见的肿瘤之一，也是发病率和死亡率的普遍原因。卡博替尼是一种针对肾细胞癌的强力多受体酪氨酸激酶抑制剂，对 HCC 的治疗也可能有用。
本综述描述了卡博替尼的化学结构、药理特性以及根据来自 I 期和后期临床试验的数据对其在 HCC 治疗中的疗效的现有认识。还描述了正在进行的测试卡博替尼的研究，包括单独使用或与其他药物联合使用的研究。
尽管最近在使用卡博替尼治疗诊断为肝细胞癌的患者方面取得了进展，但仍需要更多的数据，以使临床医生能够更好地决定如何治疗特定的患者亚组。
